Health‐related quality of life (HRQoL) · adults with advanced illness and their unpaid caregivers/families
1 finding from 1 review
HRQoL: using EQ‐5D (range from 0 to 1; higher values indicate better quality of life · adults with displaced and undisplaced hip fractures
1 finding from 1 review
Quality of life: 1. General quality of life · Adults with co‐morbid PTSD and SMI
1 finding from 1 review
Health‐related quality of life (EQ‐5D) ‐ Long‐term improvement: > 3 months Scale: 0 to 1, higher is better · carpal tunnel syndrome
1 finding from 1 review
Health‐related quality of life Assessed by: SeiQoL‐DW (higher scores mean better quality of life) · sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis
1 finding from 1 review
Quality of life (patient) (1 to 6 months post intervention) DEMQOL (higher score = better quality of life) · people with dementia and their carers
1 finding from 1 review
Intervention not reported
Quality of Life SF‐36 Mental Summary score (scale 0 to 100, higher score indicates better quality of life) · adults with intermittent claudication
1 finding from 1 review
Quality of life: 1. General quality of life · Adults with co‐morbid PTSD and SMI
1 finding from 1 review
Intervention not reported
Health‐related quality of life ‐ all trials Higher scores indicate improved health‐related quality of life · patients with chronic obstructive pulmonary disease who do not qualify for home oxygen therapy
1 finding from 1 review
Health‐related quality of life measured using QUALID (12–45, higher score indicates poorer quality of life) · people with dementia
1 finding from 1 review
Health‐related quality of life measured using QUALID (12–45, higher score indicates poorer quality of life) · people with dementia
1 finding from 1 review
QoL · people with burn wounds likely to develop hypertrophic scarring
1 finding from 1 review
QoL · people with burn wounds likely to develop hypertrophic scarring
1 finding from 1 review
IBDQ at week 8 · people with inflammatory bowel disease
1 finding from 1 review
Intervention not reported
HRQoL Using EQ‐5D (range 0 to 1) and HOOS (range 0 to 100). A higher score indicates better quality of life. · adults following hip fracture surgery
It is very uncertain whether the intervention changes HRQoL Using EQ‐5D (range 0 to 1) and HOOS (range 0 to 100). A higher… (very low certainty).
1 finding from 1 review
Health‐related quality of life Dementia‐specific quality of life measure (QUALIDEM) (higher scores = better) · older adults living in long‐term residential care including, but not limited to, dementia‐specific care settings
1 finding from 1 review
no estimate extracted
33 participants
Very low
Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly showed no clear difference in mean change in VAS (higher scores suggest greater disease activity… compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review
Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly showed no clear difference in mean change in VAS (higher scores suggest greater disease activity… compared with placebo + 26‐week taper (moderate certainty).
1 finding from 1 review
Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab every other week showed no clear difference in mean change in VAS (higher scores suggest greater disease activity… compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review
Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab every other week showed no clear difference in mean change in VAS (higher scores suggest greater disease activity… compared with placebo + 26‐week taper (moderate certainty).
1 finding from 1 review